New research has shown that neuroendocrine tumors are more common than
previously thought. Progress in our understanding of the molecular
pathogenesis of these not-so-rare cancers has resulted in renewed
interest in developing innovative therapeutic options. In particular,
novel molecular targeted agents have been shown to have significant
anti-tumor activity, and integration of these therapies has led to
critical advances in management.
In this volume, an outstanding group of the world's leaders in the field
have assembled to convey their knowledge of the epidemiology, biology,
and management of all the major types of neuroendocrine tumors. The book
takes a multi-modality approach to understanding disease processes and
therapeutics, including chapters on medical and surgical treatment as
well as a chapter devoted to imaging. Throughout, the authors emphasize
recent advances in our understanding of molecular biology and the
subsequent emerging therapeutic options.